On the other hand, a randomised Phase 2 study comparing cabazitaxel versus weekly paclitaxel as neoadjuvant therapy in patients with early HER2-negative breast cancer demonstrated inferior activity of cabazitaxel with respect to the pathological complete response rate.15 The efficacy of cabazitaxel in other types of cancer has also been evaluated with encouraging results in recent studies.16,17 Regarding toxicity, cabazitaxel was tolerated fairly well in most of the patients. This evidence concerns the gene ERBB2 and breast cancer.